• 主题
高级搜索  >
历史搜索 清空历史
首页> 美国卫生研究院文献>International Journal of Hematology-Oncology and Stem Cell Research >The Confirmation of Safety for the Intensified Conditioning Regimens: A Retrospective Study of Allogeneic Hematopoietic Stem Cell Transplantation for Non-Remission Hematological Malignant Diseases
【2h】

The Confirmation of Safety for the Intensified Conditioning Regimens: A Retrospective Study of Allogeneic Hematopoietic Stem Cell Transplantation for Non-Remission Hematological Malignant Diseases

机译：强化条件治疗方案的安全性确认：同种异体造血干细胞移植治疗非缓解性血液系统恶性疾病的回顾性研究

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

>Background: The prognosis of allogeneic hematopoietic stem cell transplantation (HSCT) for non-remission hematological malignant diseases is usually unfavorable. The most uncontrollable factor is residual disease or relapse. To overcome this problem, intensified conditioning regimens- sequential and/or additional chemotherapy to the standard regimen- could be effective. However, increasing the intensity of conditioning might also lead to more complications. >Materials and Methods: We retrospectively analyzed 81 patients with non-remission disease who received allogeneic HSCT in our institution between 2007 and 2011. >Results: 55.6% in 36 myeloablative conditioning patients and 46.7% in 45 reduced-intensity conditioning patients received intensified conditioning. The 5-year probability of overall survival was 35.0% and 17.1% in the standard and intensified group, respectively (p=0.027). Relapse mortality was 30% in the standard regimen group and 36.6% in the intensified regimen group (p=0.54). Transplant-related mortality (TRM) at 30 and 100 days was 5%, 17.1% (p=0.086) and 27.5%, 34.2% (p=0.52) in the standard and intensified group, respectively. There was no difference in TRM between the 2 groups at 30 days and 100 days. >Conclusion: The results of the study confirm the safety of the intensified conditioning regimen. Meanwhile, it could be considered as one of the few methods available to reduce the tumor burden before HSCT for refractory malignant diseases.
机译：>背景：对于非缓解性血液恶性疾病，同种异体造血干细胞移植（HSCT）的预后通常是不利的。最不可控制的因素是残留疾病或复发。为了克服这个问题，强化调理方案（对标准方案进行序贯和/或附加化疗）可能是有效的。但是，增加调理的强度也可能导致更多的并发症。 >材料和方法：我们回顾性分析了2007年至2011年间在我院接受异基因HSCT的81例非缓解性疾病患者。>结果：在36例清髓性调理患者中，55.6％ 45名低强度调理患者中有46.7％接受了强化调理。标准组和强化组的5年总生存率分别为35.0％和17.1％（p = 0.027）。标准治疗组的复发死亡率为30％，强化治疗组的复发死亡率为36.6％（p = 0.54）。标准组和强化组在30天和100天时的移植相关死亡率（TRM）分别为5％，17.1％（p = 0.086）和27.5％，34.2％（p = 0.52）。两组在30天和100天时的TRM没有差异。 >结论：研究结果证实了强化调理方案的安全性。同时，它可以被认为是在难治性恶性肿瘤HSCT之前减少肿瘤负担的少数可用方法之一。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号